Sanofi’s new facility will significantly increase domestic production of life-saving vaccines TORONTO — The Ontario government joined Sanofi to celebrate the grand opening of their new, $800 million vaccine manufacturing facility at its Toronto campus. The new building, spanning approximately 200,000 square feet, will produce pediatric and adult vaccines for pertussis (whooping cough), diphtheria and tetanus, significantly increasing the country’s …
Beyfortus approved in China for the prevention of RSV disease in infants
London – AstraZeneca and Sanofi’s Beyfortus (nirsevimab), a long-acting monoclonal antibody, has been approved in China for the prevention of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) in neonates and infants entering or during their first RSV season.1 Beyfortus is anticipated to be available during the upcoming 2024-2025 RSV season. Beyfortus is the first approved preventive option to protect against RSV in a …